Clinical Trials Directory

Trials / Completed

CompletedNCT00197613

The Adult Antiretroviral Treatment and Resistance Study (Tshepo)

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
650 (planned)
Sponsor
Harvard School of Public Health (HSPH) · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The "Adult Antiretroviral Treatment and Resistance Study," hereafter referred to as "The Tshepo Study," is the first large-scale research study of antiretroviral therapy to treat AIDS and HIV infection in Botswana. The Tshepo Study is an open-label, randomized study comparing: (1) the rate of development and specific types of drug resistance mutations with various antiretroviral combination therapies to HIV-1C, the subtype of HIV found in southern Africa, and (2) the short and long-term effectiveness of two operational modifications of Directly Observed Therapy (DOT) medication adherence strategies for antiretroviral therapy. Specifically, treatment follow-up via the Standard of Care, the national standard of care as it evolves in Botswana, with intensive clinic-based follow up including regular adherence education sessions, will be compared to Community-Based Directly Observed Therapy (Com-DOT). Com-DOT involves the SOC with added community or family-based DOT. This Com-DOT component would involve a trained, community or family-based Medication Partner ("mopati") who observes the patient take his or medications daily.

Conditions

Interventions

TypeNameDescription
DRUG(A) zidovudine, lamivudine and nevirapine
DRUG(B) zidovudine, lamivudine and efavirenz
DRUG(C) zidovudine, didanosine, and nevirapine
DRUG(D) zidovudine, didanosine, and efavirenz
DRUG(E) stavudine, lamivudine, and nevirapine
DRUG(F) stavudine, lamivudine and efavirenz
PROCEDUREAdherence Strategy Standard of Care (SOC)
PROCEDUREAdherence Strategy Community-Based DOT

Timeline

Start date
2002-12-01
Completion
2007-12-01
First posted
2005-09-20
Last updated
2012-09-17

Locations

1 site across 1 country: Botswana

Source: ClinicalTrials.gov record NCT00197613. Inclusion in this directory is not an endorsement.